ReviewJournal of Parkinson's disease2016
Pathophysiological Concepts and Treatment of Camptocormia.
Review in Journal of Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Botulinum Toxin for Axial Postural Abnormalities in Parkinson's Disease: A Systematic Review.Toxins · 2024Pooled it
- The Study of Subthalamic Deep Brain Stimulation for Parkinson Disease-Associated Camptocormia.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Clinical Algorithm-Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Acute fentanyl and xylazine co-exposure uniquely increase the excitability of dopamine type 2 receptor-expressing striatal medium spiny neurons.Journal of neurophysiology · 2026Article
- Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Frozen in Addiction: A New Wave of Drug-Induced Movement Disorders?Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Parkinson's disease-associated camptocormia: biopsy-confirmed focal myositis and treatment options.Journal of neurology · 2025Article
- Camptocormia as a Phenotypic Variant of FSHD in the Elderly: Clinical, Genetic, and Imaging Features.European journal of neurology · 2025Article
- Continuous mobile measurement of camptocormia angle using four accelerometers.Medical & biological engineering & computing · 2024Article
- Wearable sensor devices can automatically identify the ON-OFF status of patients with Parkinson's disease through an interpretable machine learning model.Frontiers in neurology · 2024Article
- Myofibrillar myopathy: a rare but important differential diagnosis of camptocormia in a patient with Parkinson's Disease.Neurological research and practice · 2023Article
- Characterizing Camptocormia in Parkinson's Disease Using Muscle Ultrasonography.Journal of Parkinson's disease · 2023Article
- Temporary Stimulation Switch-off Successfully Applied in a Dystonic Camptocormia Patient.Movement disorders clinical practice · 2022Article
- From Collar to Coccyx: Truncal Movement Disorders: A Clinical Review.Movement disorders clinical practice · 2021Review
- The Virtual Spine Examination: Telemedicine in the Era of COVID-19 and Beyond.Global spine journal · 2021Article
- Deep brain stimulation in the subthalamic nuclei alters postural alignment and adaptation in Parkinson's disease.PloS one · 2021Article
- Hand, foot, and spine deformities in parkinsonian disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- Recent advancements in lateral trunk flexion in Parkinson disease.Neurology. Clinical practice · 2019Review
- An Unusual Cause of Camptocormia.Tremor and other hyperkinetic movements (New York, N.Y.) · 2019Article
- Injection of Onabotulinum Toxin A into the Bilateral External Oblique Muscle Attenuated Camptocormia: A Prospective Open-Label Study in Six Patients with Parkinson's Disease.Neurology and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Camptocormia is a disabling pathological, non-fixed, forward bending of the trunk. The clinical definition using only the bending angle is insufficient; it should include the subjectively perceived inability to stand upright, occurrence of back pain, typical individual complaints, and need for walking aids and compensatory signs (e.g. back-swept wing sign). Due to the heterogeneous etiologies of camptocormia a broad diagnostic approach is necessary. Camptocormia is most frequently encountered in movement disorders (PD and dystonia) and muscles diseases (myositis and myopathy, mainly facio-scapulo-humeral muscular dystrophy (FSHD)). The main diagnostic aim is to discover the etiology by looking for signs of the underlying disease in the neurological examination, EMG, muscle MRI and possibly biopsy. PD and probably myositic camptocormia can be divided into an acute and a chronic stage according to the duration of camptocormia and the findings in the short time inversion recovery (STIR) and T1 sequences of paravertebral muscle MRI. There is no established treatment of camptocormia resulting from any etiology. Case series suggest that deep brain stimulation (DBS) of the subthalamic nucleus (STN-DBS) is effective in the acute but not the chronic stage of PD camptocormia. In chronic stages with degenerated muscles, treatment options are limited to orthoses, walking aids, physiotherapy and pain therapy. In acute myositic camptocormia an escalation strategy with different immunosuppressive drugs is recommended. In dystonic camptocormia, as in dystonia in general, case reports have shown botulinum toxin and DBS of the globus pallidus internus (GPi-DBS) to be effective. Camptocormia in connection with primary myopathies should be treated according to the underlying illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.